Drug design, development and therapyAug 3, 2026

Side Effects Linked to Incretin-Based Diabetes Treatments: Causes, Care, and Risk Reduction

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Aug 4, 2026

Abstract

Incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1RAs), provide sustained weight reduction and improved glycaemic control.

GLP-1RAs are associated with cardiovascular and renal benefits.
Safety concerns persist regarding adverse events that could impact treatment adherence.
Common adverse events and emerging safety signals related to GLP-1RAs are evaluated.
Clinical, mechanistic, and pharmacovigilance evidence is reviewed to assess safety profiles.

Simplified

Incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1RAs), are established therapies for obesity and type 2 diabetes mellitus, providing sustained weight reduction, improved glycaemic control, cardiovascular and renal benefits. Despite these established benefits, safety concerns remain an important clinical issue because adverse events may affect treatment persistence, patient acceptability, and clinical decision-making. This review evaluates a number of safety profiles of GLP-1RAs using clinical, mechanistic, and pharmacovigilance evidence, with attention to both common adverse events and emerging safety signals.

Full Text

Full text is available at the source.

View Full Text ↗

Side Effects Linked to Incretin-Based Diabetes Treatments: Causes, Care, and Risk Reduction

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief